PDF(Pubmed)
Abstract：
Congenital heart disease (CHD) is the most common birth defect, requiring invasive surgery often before a child\'s first birthday. Current materials used during CHD surgery lack the ability to grow, remodel, and regenerate. To solve those limitations, 3D bioprinting is an emerging tool with the capability to create tailored constructs based on patients\' own imaging data with the ability to grow and remodel once implanted in children with CHD. It has the potential to integrate multiple bioinks with several cell types and biomolecules within 3D-bioprinted constructs that exhibit good structural fidelity, stability, and mechanical integrity. This review gives an overview of CHD and recent advancements in 3D bioprinting technologies with potential use in the treatment of CHD. Moreover, the selection of appropriate biomaterials based on their chemical, physical, and biological properties that are further manipulated to suit their application are also discussed. An introduction to bioink formulations composed of various biomaterials with emphasis on multiple cell types and biomolecules is briefly overviewed. Vasculogenesis and angiogenesis of prefabricated 3D-bioprinted structures and novel 4D printing technology are also summarized. Finally, we discuss several restrictions and our perspective on future directions in 3D bioprinting technologies in the treatment of CHD.
摘要：
先天性心脏病（CHD）是最常见的出生缺陷，通常在孩子的第一个生日之前需要进行侵入性手术。目前在CHD手术中使用的材料缺乏生长能力，改造，并再生。为了解决这些限制，3D生物打印是一种新兴的工具，能够根据患者自己的成像数据创建量身定制的结构，一旦植入冠心病儿童，就能够进行生长和重塑。它有可能将多种生物墨水与几种细胞类型和生物分子整合在3D生物打印的构建体中，这些构建体表现出良好的结构保真度。稳定性,和机械完整性。这篇综述概述了CHD以及3D生物打印技术的最新进展，这些技术在CHD的治疗中具有潜在的用途。此外，根据其化学性质选择合适的生物材料，物理，和进一步操纵，以适应其应用的生物学特性也进行了讨论。简要概述了由各种生物材料组成的生物墨水制剂的介绍，重点是多种细胞类型和生物分子。还总结了预制3D生物打印结构的血管发生和血管生成以及新型4D打印技术。最后,我们讨论了3D生物打印技术在冠心病治疗中的一些限制以及我们对未来方向的看法.
